1. Short title This Act may be cited as the Informing Opioid Prescribing Through Evidence-Based Guidelines Act of 2018 . 2. Study and report (a) Study The Commissioner of Food and Drugs shall develop high-quality, evidence-based opioid analgesic prescribing guidelines for the indication-specific treatment of acute pain in the relevant therapeutic areas where such high-quality, evidence-based opioid analgesic prescribing guidelines— (1) do not exist; and (2) are not redundant of existing guidelines. (b) Public input In conducting the study under subsection (a), the Commissioner of Food and Drugs shall— (1) conduct a public workshop, open to representatives of State medical societies and medical boards, various medical specialties including pain medicine specialty societies, patient groups, universities, and others; and (2) provide a period for the submission of comments by the public. (c) Report Not later than the date that is 2 years after the date of enactment of this Act, the Commissioner of Food and Drugs shall submit to the Congress, and post on the public website of the Food and Drug Administration, a report on the results of the study under subsection (a). (d) Updates On a biennial basis after submission of the report required by subsection (c), the Commissioner of Food and Drugs shall— (1) update the study under subsection (a), informed by public input described in subsection (b)